logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Hematology (non-malignant) drugs

    FiltersReset Filters
    30 results

    • adakveo

      (crizanlizumab)
      Novartis Pharmaceuticals Corporation
      Usage: ADAKVEO® is indicated for reducing the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 and older with sickle cell disease.

    • alvaiz

      (Eltrombopag)
      Teva Pharmaceuticals, Inc.
      Usage: ALVAIZ (eltrombopag) is indicated for treating thrombocytopenia in patients with persistent or chronic immune thrombocytopenia, chronic hepatitis C, and severe aplastic anemia who have not responded adequately to other therapies. It is not approved for myelodysplastic syndromes or with direct-acting antiviral agents for hepatitis C.

    • cablivi

      (caplacizumab)
      Genzyme Corporation
      Usage: CABLIVI is indicated for treating adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), used alongside plasma exchange and immunosuppressive therapy.

    • edarbi

      (Azilsartan kamedoxomil)
      Azurity Pharmaceuticals, Inc.
      Usage: Edarbi is indicated for treating hypertension in adults to lower blood pressure, thereby reducing the risk of cardiovascular events such as strokes and myocardial infarctions. It can be used alone or with other antihypertensive medications as part of comprehensive cardiovascular risk management.

    • edarbyclor

      (Azilsartan kamedoxomil and chlorthalidone)
      Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals)
      Usage: Edarbyclor is indicated for treating hypertension to lower blood pressure, particularly in patients not adequately controlled on monotherapy. It may also serve as initial therapy for those needing multiple drugs to reach blood pressure goals, reducing the risk of cardiovascular events like strokes and heart attacks.

    • eliquis

      (apixaban)
      E.R. Squibb & Sons, L.L.C.
      Usage: ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in nonvalvular atrial fibrillation, as well as for the prophylaxis and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). It also reduces the risk of recurrence of DVT and PE post-therapy.

    • feraheme

      (ferumoxytol)
      AMAG Pharmaceuticals, Inc.
      Usage: Feraheme is indicated for treating iron deficiency anemia (IDA) in adult patients who are intolerant to oral iron, have had an unsatisfactory response to oral iron, or have chronic kidney disease (CKD).

    • granix

      (tbo-filgrastim)
      Cephalon, LLC
      Usage: GRANIX is indicated for reducing the duration of severe neutropenia in adults and pediatric patients (1 month and older) with non-myeloid malignancies undergoing myelosuppressive anticancer treatments that are likely to cause febrile neutropenia.

    • inderal

      (propranolol hydrochloride)
      ANI Pharmaceuticals, Inc.
      Usage: Inderal LA is indicated for managing hypertension (alone or with other agents), reducing angina frequency, prophylaxis of migraine headaches, and improving symptoms in patients with hypertrophic subaortic stenosis. It is not recommended for hypertensive emergencies or for treating acute migraine attacks.

    • injectafer

      (Ferric Carboxymaltose Injection)
      American Regent, Inc.
      Usage: Injectafer is indicated for treating iron deficiency anemia in patients aged 1 year and older with oral iron intolerance or unsatisfactory response, and in non-dialysis dependent chronic kidney disease. It also treats iron deficiency in adults with heart failure (NYHA class II/III) to improve exercise capacity.